Histamine dihydrochloride injection - Immune Pharmaceuticals

Drug Profile

Histamine dihydrochloride injection - Immune Pharmaceuticals

Alternative Names: Ceplene; Maxamine

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; Immune Pharmaceuticals Inc; Karolinska University Hospital; MegaPharm Ltd; Nordic Group; Sahlgrenska University Hospital
  • Class Antineoplastics; Antivirals; Imidazoles; Small molecules
  • Mechanism of Action CYBB protein inhibitors; NADPH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase I/II Chronic myelomonocytic leukaemia
  • Preclinical Solid tumours
  • Discontinued Alcoholic hepatitis; Hepatitis C; Malignant melanoma; Non-alcoholic steatohepatitis

Most Recent Events

  • 07 Aug 2017 Cytovia Oncology files for world-wide patent protection for histamine dihydrochloride injection
  • 07 Aug 2017 Pharmacodynamics data from a preclinical trial in Chronic myelomonocytic leukaemia released by Cytovia Oncology
  • 13 Jul 2017 Cytovia Oncology files for world-wide patent protection for histamine dihydrochloride
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top